Jornal de Ensaios Clínicos
Acesso livre

Abstrato

Conceptual Analysis of COVID-19 in Phase 3 Clinical Trials: a Hierarchical

Javier Burgos-Salcedo*

The emergence of a novel SARS-CoV-2 coronavirus at the end of 2019 and its accelerated spread worldwide to become a pandemic has had, from the medical biotechnology point of view, an unprecedented global response, to the point that there are currently 176 vaccine candidates in the preclinical stage and 66 in clinical stage. The purpose of the present work is to elaborate a hierarchical landscape of the current status of 12 phase 3 vaccines, taking into account their attributes of technological platform, safety, and efficacy. The methodology used was that of conceptual knowledge representation, resulting in, firstly, appropriate classification of stage 3 vaccines, in four categories, the first made up of the BBIBP-CorV, BBV152, CoronoVac and Wuhan Institute vaccines; the second Medicago's CoVLP vaccine; the third, conformed by NVX-CoV2373, BNT162, AstraZeneca (AZD1222); and the fourth, conformed by Ad26.COV2. S and Ad5-nCoV. This hierarchy of COVID-19 vaccines enables the development of adaptable strategies to implement cost-effective clinical trials aimed at controlling the pandemic.